IMPEDIMED LIMITED — Capital/Financing Update 2008

Oct 2, 2008

==> picture [109 x 104] intentionally omitted <==

----- Start of picture text ----- ASX : IPD----- End of picture text -----

3-Oct-2008

ASX RELEASE

Agreement Announced with Metagenics Inc in the USA

ImpediMed Limited attach for the information of shareholders a press release issued in the United States today announcing an agreement between ImpediMed’s US subsidiary ImpediMed, Inc and Metagenics, Inc.

Under the agreement ImpediMed’s fluid status and body composition division will supply its DF50 device to Metagenics in the United States, for resale to the healthcare professionals market in conjunction with Metagenics own research-based health and wellness products and programs.

For more information contact :

Greg Brown Chief Executive Officer

+61-7-3860-3700

www.impedimed.com

ImpediMed and Metagenics Announce Agreement

Brisbane, Australia and San Clemente, California, Oct. 2, 2008 – ImpediMed Ltd, a pioneer in the medical applications of bioimpedance technology and Metagenics, Inc., a global leader in science-based nutraceutical products, medical foods, and therapeutic lifestyle change programs, today announced an agreement to distribute ImpediMed technology in the United States and Canada. Metagenics’ Australian affiliate, Health World, Ltd, has been a long-standing customer of the Brisbane-based medical device manufacturer.

“We’ve seen the synergies of combining ImpediMed’s products for assessing fat and fluid status with our own research-based health and wellness products and programs, which we market to healthcare professionals,” said Mike Katke, VP of Medical Marketing for San Clemente, California-based Metagenics. “Their scientifically-grounded approach and the reliability and portability of their technology made offering ImpediMed to our customers a simple decision.”

ImpediMed CEO Greg Brown said, “Metagenics has been an outstanding Australian partner using ImpediMed’s body composition analysis devices for several years. This expanded relationship makes sense in light of our mutual focus on addressing wellness and healthier life styles.”

About Metagenics, Inc.

Metagenics, Inc. is a life sciences company and leading developer and manufacturer of science-based nutraceuticals medical foods, and therapeutic lifestyle change programs marketed to healthcare practitioners worldwide. It is headquartered in San Clemente, Calif. with manufacturing and multiple research facilities located in Gig Harbor, Wash., including its MetaProteomics® Nutrigenomics Research Center and its Functional Medicine Research Center[SM] for human clinical research. Metagenics holds multiple proprietary formula patents and produces over 400 research-based products to optimize health. The company demonstrates its commitment to purity and quality through its certifications for Good Manufacturing Practices (GMP) from the NPA, NSF International, and TGA. For more information about Metagenics, please visit www.metagenics.com

About ImpediMed Limited

ImpediMed Limited develops and globally markets medical device systems for use in non-invasive screening and monitoring of fluid status and body composition. ImpediMed’s product range includes medical devices for body composition analysis and for use by clinicians in the clinical assessment of secondary lymphoedema in female breast cancer survivors. ImpediMed’s products are TGA and FDA cleared as well as CE marked for global distribution. For more information about ImpediMed, please visit www.impedimed.com

Contact:

Joseline Davison Metagenics, Inc. 949-369-3406 josielorenzo@metagenics.com Jack Butler ImpediMed, Inc. 585-248-2554 jbutler@impedimed.com